论文部分内容阅读
:〔目的〕对比观察阿霉素(ADM)多相脂质体与游离ADM治疗晚期肝癌近期疗效及副作用。〔方法〕1997年3月～1998年6月87例晚期肝癌患者,随机分成两组,A组为ADM多相脂质体介入化疗组(治疗组),B组为游离ADM介入化疗组(对照组)。〔结果〕平均生存期1年生存率两组无明显差别,近期疗效A组优于B组,毒副反应A组较B组轻。〔结论〕两种治疗方法平均生存期无明显差别,ADM多相脂质体介入化疗可提高近期疗效,降低毒副反应,提高病人生活质量。
: [Objective] To compare the short-term efficacy and side effects of adriamycin (ADM) multiphase liposomes versus free ADM in the treatment of advanced liver cancer. [Method] Eighty-seven patients with advanced liver cancer from March 1997 to June 1998 were randomly divided into two groups. Group A was ADM multiphase liposomal intervention chemotherapy group (treatment group), and Group B was free ADM intervention chemotherapy group (control group). group). 〔Results〕 There was no significant difference in the 1-year survival rate between the two groups. The short-term efficacy of group A was better than that of group B, and toxic side effects were lighter in group A than in group B. [Conclusion] There was no significant difference in the mean survival time between the two treatment methods. ADM multiphase liposomal intervention chemotherapy can improve the short-term efficacy, reduce toxic side effects, and improve the quality of life of patients.